---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-003383"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2023-03-23T23:59:59+00:00"
generated_at: "2026-06-17T18:33:33.836334+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Monopar FY2022 net loss $10.5M; Validive interim readout due next week; camsirubicin dose-escalation continues

## Summary
- Net loss FY2022 $10.5M ($0.83/share) vs $9.1M ($0.73/share) in 2021; cash $13.1M.
- Validive Phase 2b/3 VOICE trial interim analysis go/no-go readout expected by end of next week.
- Camsirubicin Phase 1b enrolling 5th dose level (650 mg/m²); no cardiotoxicity, 75% no hair loss.
- CFO Kim Tsuchimoto appointed to board; board size increased to six.
- Current funds expected to cover camsirubicin topline results by end 2023; additional funding sought within 12 months.

## SEC filing metadata
- accession: 0001654954-23-003383
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2023-03-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000165495423003383/0001654954-23-003383-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000165495423003383/mnpr_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-003383
- JSON: https://secwatch.observer/filing/0001654954-23-003383.json
- Plain text: https://secwatch.observer/filing/0001654954-23-003383.txt

## Key facts
- Earnings Releases
  Monopar Therapeutics reported financial results for fourth quarter and full year ended December 31, 2022.
  - Period: fourth quarter and full year ended December 31, 2022
  - Result: reported results
  source text: On March 23, 2023, Monopar Therapeutics Inc. issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645469/000165495423003383/0001654954-23-003383-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.